000078 海王生物
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入21,512,920-12.38%30,317,28836,418,77037,834,85941,053,584
减:营业总成本21,460,284-11.96%30,630,05836,503,98437,782,45940,327,347
    其中:营业成本19,531,505-11.71%27,444,70732,865,44534,045,03536,655,494
               财务费用449,888-15.90%806,282943,621905,212807,226
               资产减值损失11,2211,092.23%(518,749)(962,355)(550,406)(197,520)
公允价值变动收益141-98.59%6,38417,75256,84737,706
投资收益91,633-2,046.91%11,147(45,418)(143,505)37,329
    其中:对联营企业和合营企业的投资收益3582,685.48%4,318(26,996)(106,917)46,675
营业利润165,529-38.00%(1,062,938)(1,468,030)(854,588)561,017
利润总额167,901-37.56%(1,081,694)(1,458,474)(853,160)576,310
减:所得税费用99,660-30.32%85,617260,559138,290318,443
净利润68,240-45.77%(1,167,311)(1,719,033)(991,450)257,868
减:非控股权益42,537-46.58%26,104(29,088)35,519164,572
股东净利润25,703-44.39%(1,193,415)(1,689,945)(1,026,969)93,295

市场价值指针
每股收益 (元) *0.010-44.32%-0.454-0.642-0.3910.036
每股派息 (元) *------------
每股净资产 (元) *0.693-39.97%0.6821.0921.7052.117
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容